Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

CB2R agonist GW405833 alleviates acute liver failure in mice via inhibiting HIF-1α-mediated reprogramming of glycometabolism and macrophage proliferation

Acta Pharmacologica Sinica volume 44, pages 1391–1403 (2023)Cite this article

Abstract

The inflammatory responses involving infiltration and activation of liver macrophages play a vital role in acute liver failure (ALF). In the liver of ALF mice, cannabinoid receptor 2 (CB2R) is significantly upregulated on macrophages, while CB2R agonist GW405833 (GW) could protect against cell death in acute liver damage. In this study, we investigated the molecular mechanisms underlying the protective effects of GW against ALF in vivo and in vitro from a perspective of macrophage glycometabolism. Mice were pretreated with GW (10 mg/kg, i.p.), then were injected with D-GalN (750 mg/kg, i.p.) and LPS (10 mg/kg, i.p.) to induce ALF. We verified the protective effects of GW pretreatment in ALF mice. Furthermore, GW pretreatment significantly reduced liver macrophage infiltration and M1 polarization, and inhibited the release of inflammatory factors TNF-α and IL-1β in ALF mice. These protective effects were eliminated by CB2R antagonist SR144528 or in CB2R−/− ALF mice. We used LPS-stimulated RAW264.7 cells as an in vitro M1 macrophage-centered model of inflammatory response, and demonstrated that pretreatment with GW (10 μM) significantly reduced glucose metabolism by inhibiting glycolysis, which inhibited LPS-induced macrophage proliferation and inflammatory cytokines release. We verified these results in a stable CB2R−/− RAW264.7 cell line. Moreover, we found that GW significantly inhibited the expression of hypoxia inducible factor 1α (HIF-1α). Using a stable HIF-1α−/− RAW264.7 cell line, we confirmed that GW reduced the release of inflammatory cytokines from macrophages and inhibited glycolysis by downregulating HIF-1α expression. In conclusion, activation of CB2Rs inhibits the proliferation of hepatic macrophages and release of inflammatory factors in ALF mice through downregulating HIF-1α to inhibit glycolysis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Survival analysis of grouped mice.
Fig. 2: Protective effect of GW in ALF.
Fig. 3: Effects of CB2R activation on macrophage activation, inflammation, and apoptosis of liver cells in ALF.
Fig. 4: Effect of CB2R activation on macrophage proliferation and release of inflammatory cytokines.
Fig. 5: Effect of CB2R activation on glucose metabolism in LPS-activated macrophages.
Fig. 6: Effects of CB2R knockdown for LPS-activated macrophages on cell proliferation, release of inflammatory factors and glucose metabolism.
Fig. 7: Effect of HIF-1α knockdown on GW activated CB2R to alter LPS-stimulated macrophages.
Fig. 8: Differential liver damage in WT and CB2R−/− mice.
Fig. 9: Differential expression of HIF-1α in liver macrophages of ALF in WT and CB2R−/− mice.

Similar content being viewed by others

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Louvet A, Teixeira-Clerc F, Chobert MN, Deveaux V, Pavoine C, Zimmer A, et al. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology. 2011;54:1217–26.

    Article  CAS  PubMed  Google Scholar 

  2. Chen J, Huang ZB, Li H, Zheng X, Chen JJ, Wang XB, et al. Early diagnostic biomarkers of sepsis for patients with acute-on-chronic liver failure: a multicenter study. Infect Dis Ther. 2021;10:281–90.

    Article  PubMed  Google Scholar 

  3. Chen J, Huang ZB, Fan XG, Hu XW, Qi M, Liao CJ, et al. Potential predictors for prognosis and postpartum recovery time of acute fatty liver of pregnancy. BMC Pregnancy Childbirth. 2020;20:601.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Olah A, Szekanecz Z, Biro T. Targeting cannabinoid signaling in the immune system: “High”-ly exciting questions, possibilities, and challenges. Front Immunol. 2017;8:1487.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol. 2017;17:306–21.

    Article  CAS  PubMed  Google Scholar 

  6. Triantafyllou E, Woollard KJ, McPhail MJW, Antoniades CG, Possamai LA. The role of monocytes and macrophages in acute and acute-on-chronic liver failure. Front Immunol. 2018;9:2948.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Mihm S, Danger-Associated Molecular Patterns (DAMPs): Molecular triggers for sterile inflammation in the liver. Int J Mol Sci. 2018;19:3104.

  8. Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1/M2 polarization. Eur J Pharmacol. 2020;877:173090.

    Article  PubMed  Google Scholar 

  9. Kolodziejczyk AA, Federici S, Zmora N, Mohapatra G, Dori-Bachash M, Hornstein S, et al. Acute liver failure is regulated by MYC- and microbiome-dependent programs. Nat Med. 2020;26:1899–911.

    Article  CAS  PubMed  Google Scholar 

  10. Liang DY, Liu LM, Ye CG, Zhao L, Yu FP, Gao DY, et al. Inhibition of UII/UTR system relieves acute inflammation of liver through preventing activation of NF-kappaB pathway in ALF mice. PLoS One. 2014;8:e64895.

    Article  PubMed  Google Scholar 

  11. Zannetti C, Roblot G, Charrier E, Ainouze M, Tout I, Briat F, et al. Characterization of the inflammasome in human Kupffer cells in response to synthetic agonists and pathogens. J Immunol. 2016;197:356–67.

    Article  CAS  PubMed  Google Scholar 

  12. Viola A, Munari F, Sanchez-Rodriguez R, Scolaro T, Castegna A. The metabolic signature of macrophage responses. Front Immunol. 2019;10:1462.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Jha AK, Huang SC, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva E, et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity. 2015;42:419–30.

    Article  CAS  PubMed  Google Scholar 

  14. Freemerman AJ, Johnson AR, Sacks GN, Milner JJ, Kirk EL, Troester MA, et al. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J Biol Chem. 2014;289:7884–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Palsson-McDermott EM, O’Neill LAJ. Targeting immunometabolism as an anti-inflammatory strategy. Cell Res. 2020;30:300–14.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Huang ZB, Zheng YX, Li N, Cai SL, Huang Y, Wang J, et al. Protective effects of specific cannabinoid receptor 2 agonist GW405833 on concanavalin A-induced acute liver injury in mice. Acta Pharmacol Sin. 2019;40:1404–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Huang Z, Wang H, Wang J, Zhao M, Sun N, Sun F, et al. Cannabinoid receptor subtype 2 (CB2R) agonist, GW405833 reduces agonist-induced Ca2+ oscillations in mouse pancreatic acinar cells. Sci Rep. 2016;6:29757.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Denaes T, Lodder J, Chobert MN, Ruiz I, Pawlotsky JM, Lotersztajn S, et al. The Cannabinoid Receptor 2 protects against alcoholic liver disease via a macrophage autophagy-dependent pathway. Sci Rep. 2016;6:28806.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Tomar S, Zumbrun EE, Nagarkatti M, Nagarkatti PS. Protective role of cannabinoid receptor 2 activation in galactosamine/lipopolysaccharide-induced acute liver failure through regulation of macrophage polarization and microRNAs. J Pharmacol Exp Ther. 2015;353:369–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Du Y, Ren P, Wang Q, Jiang SK, Zhang M, Li JY, et al. Cannabinoid 2 receptor attenuates inflammation during skin wound healing by inhibiting M1 macrophages rather than activating M2 macrophages. J Inflamm. 2018;15:25.

    Article  CAS  Google Scholar 

  21. Jiang P, Wang L, Zhang M, Zhang M, Wang C, Zhao R, et al. Cannabinoid type 2 receptor manipulates skeletal muscle regeneration partly by regulating macrophage M1/M2 polarization in IR injury in mice. Life Sci. 2020;256:117989.

    Article  CAS  PubMed  Google Scholar 

  22. Braun M, Khan ZT, Khan MB, Kumar M, Ward A, Achyut BR, et al. Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization. Brain Behav Immun. 2018;68:224–37.

    Article  CAS  PubMed  Google Scholar 

  23. Zhou H, Du R, Li G, Bai Z, Ma J, Mao C, et al. Cannabinoid receptor 2 promotes the intracellular degradation of HMGB1 via the autophagy-lysosome pathway in macrophage. Int Immunopharmacol. 2020;78:106007.

    Article  CAS  PubMed  Google Scholar 

  24. Luo XQ, Li A, Yang X, Xiao X, Hu R, Wang TW, et al. Paeoniflorin exerts neuroprotective effects by modulating the M1/M2 subset polarization of microglia/macrophages in the hippocampal CA1 region of vascular dementia rats via cannabinoid receptor 2. Chin Med. 2018;13:14.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Dando I, Donadelli M, Costanzo C, Dalla Pozza E, D’Alessandro A, Zolla L, et al. Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. Cell Death Dis. 2013;4:e664.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Bueno MJ, Jimenez-Renard V, Samino S, Capellades J, Junza A, Lopez-Rodriguez ML, et al. Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells. Nat Commun. 2019;10:5011.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Whiteside GT, Gottshall SL, Boulet JM, Chaffer SM, Harrison JE, Pearson MS, et al. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur J Pharmacol. 2005;528:65–72.

    Article  CAS  PubMed  Google Scholar 

  28. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia, and catalepsy. Neuropharmacology. 2005;48:658–72.

    Article  CAS  PubMed  Google Scholar 

  29. Li AL, Carey LM, Mackie K, Hohmann AG. Cannabinoid CB2 Agonist GW405833 suppresses inflammatory and neuropathic pain through a CB1 mechanism that is independent of CB2 receptors in mice. J Pharmacol Exp Ther. 2017;362:296–305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Schuelert N, Zhang C, Mogg AJ, Broad LM, Hepburn DL, Nisenbaum ES, et al. Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain. Osteoarthr Cartil. 2010;18:1536–43.

    Article  CAS  Google Scholar 

  31. Paldy E, Bereczki E, Santha M, Wenger T, Borsodi A, Zimmer A, et al. CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain. Neurochem Int. 2008;53:309–16.

    Article  CAS  PubMed  Google Scholar 

  32. Hartley JW, Evans LH, Green KY, Naghashfar Z, Macias AR, Zerfas PM, et al. Expression of infectious murine leukemia viruses by RAW264.7 cells, a potential complication for studies with a widely used mouse macrophage cell line. Retrovirology. 2008;5:1.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Chung RT, Stravitz RT, Fontana RJ, Schiodt FV, Mehal WZ, Reddy KR, et al. Pathogenesis of liver injury in acute liver failure. Gastroenterology. 2012;143:e1–e7.

    Article  CAS  PubMed  Google Scholar 

  34. Motwani MP, Gilroy DW. Macrophage development and polarization in chronic inflammation. Semin Immunol. 2015;27:257–66.

    Article  PubMed  Google Scholar 

  35. Devanney NA, Stewart AN, Gensel JC. Microglia and macrophage metabolism in CNS injury and disease: The role of immunometabolism in neurodegeneration and neurotrauma. Exp Neurol. 2020;329:113310.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Rodriguez-Prados JC, Traves PG, Cuenca J, Rico D, Aragones J, Martin-Sanz P, et al. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol. 2010;185:605–14.

    Article  CAS  PubMed  Google Scholar 

  37. Mills EL, O’Neill LA. Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal. Eur J Immunol. 2016;46:13–21.

    Article  CAS  PubMed  Google Scholar 

  38. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.

    Article  CAS  PubMed  Google Scholar 

  39. O’Neill LA, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16:553–65.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Biringer RG. Endocannabinoid signaling pathways: beyond CB1R and CB2R. J Cell Commun Signal. 2021;15:335–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Pavlou S, Wang L, Xu H, Chen M. Higher phagocytic activity of thioglycollate-elicited peritoneal macrophages is related to metabolic status of the cells. J Inflamm (Lond). 2017;14:4.

    Article  PubMed  Google Scholar 

  42. Mills EL, Kelly B, Logan A, Costa ASH, Varma M, Bryant CE, et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell. 2016;167:457–70. e13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Peyssonnaux C, Cejudo-Martin P, Doedens A, Zinkernagel AS, Johnson RS, Nizet V. Cutting edge: Essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis. J Immunol. 2007;178:7516–9.

    Article  CAS  PubMed  Google Scholar 

  44. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature. 2013;496:238–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 1996;271:32529–37.

    Article  CAS  PubMed  Google Scholar 

  46. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3:177–85.

    Article  PubMed  Google Scholar 

  47. Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MA, Sheedy FJ, Gleeson LE, et al. Pyruvate kinase M2 regulates Hif-1alpha activity and IL-1beta induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metab. 2015;21:65–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230–3.

    Article  CAS  PubMed  Google Scholar 

  49. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009;2:ra73.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Fan XG, Pei SY, Zhou D, Zhou PC, Huang Y, Hu XW, et al. Melittin ameliorates inflammation in mouse acute liver failure via inhibition of PKM2-mediated Warburg effect. Acta Pharmacol Sin. 2020;42:1256–66.

  51. Kossatz E, Maldonado R, Robledo P. CB2 cannabinoid receptors modulate HIF-1alpha and TIM-3 expression in a hypoxia-ischemia mouse model. Eur Neuropsychopharmacol. 2016;26:1972–88.

    Article  CAS  PubMed  Google Scholar 

  52. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics. 2004;84:1014–20.

    Article  CAS  PubMed  Google Scholar 

  53. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15:300–8.

    Article  CAS  PubMed  Google Scholar 

  54. Luo W, Hu H, Chang R, Zhong J, Knabel M, O’Meally R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011;145:732–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Zhan CY, Chen D, Luo JL, Shi YH, Zhang YP. Protective role of down-regulated microRNA-31 on intestinal barrier dysfunction through inhibition of NF-kappaB/HIF-1alpha pathway by binding to HMOX1 in rats with sepsis. Mol Med. 2018;24:55.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Martinez-Garcia JJ, Martinez-Banaclocha H, Angosto-Bazarra D, de Torre-Minguela C, Baroja-Mazo A, Alarcon-Vila C, et al. P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis. Nat Commun. 2019;10:2711.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Sparkenbaugh EM, Saini Y, Greenwood KK, LaPres JJ, Luyendyk JP, Copple BL, et al. The role of hypoxia-inducible factor-1alpha in acetaminophen hepatotoxicity. J Pharmacol Exp Ther. 2011;338:492–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39:126.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Lee SH, Golinska M, Griffiths JR, HIF-1-independent mechanisms regulating metabolic adaptation in hypoxic cancer cells. Cells. 2021;10:2371.

  60. Li Y, Lu L, Luo N, Wang YQ, Gao HM. Inhibition of PI3K/AKt/mTOR signaling pathway protects against d-galactosamine/lipopolysaccharide-induced acute liver failure by chaperone-mediated autophagy in rats. Biomed Pharmacother. 2017;92:544–53.

    Article  CAS  PubMed  Google Scholar 

  61. Zhong W, Qian K, Xiong J, Ma K, Wang A, Zou Y. Curcumin alleviates lipopolysaccharide induced sepsis and liver failure by suppression of oxidative stress-related inflammation via PI3K/AKT and NF-kappaB related signaling. Biomed Pharmacother. 2016;83:302–13.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81700561, 81970523), National Science and Technology Major Project (2018ZX10723203), National Natural Sciences Foundation of Hunan province (2019JJ40496, 2020JJ4877, 2020JJ4879). Sources of funding did not have any role in study design, data collection or analysis, interpretation of results, or manuscript preparation or submission. The corresponding author confirms that all the authors have full access to the full data in the study and accept responsibility to submit for publication.

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, China

    Sheng-lan Cai, Xue-gong Fan, Xing-wang Hu, Si-ya Pei, Yi-xiang Zheng, Jun Chen, Yan Huang & Ze-bing Huang

  2. Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, 410008, China

    Sheng-lan Cai, Xue-gong Fan, Yang Wang, Xing-wang Hu, Si-ya Pei, Yi-xiang Zheng, Jun Chen, Yan Huang, Ning Li & Ze-bing Huang

  3. Nation Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China

    Xue-gong Fan & Ze-bing Huang

  4. Shantou University Medical College, Shantou, 515041, China

    Jie Wu

  5. Institute of Integrative Medicine Department of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital Central South University, Changsha, 410008, China

    Yang Wang

  6. Department of Blood Transfusion, Xiangya Hospital, Clinical Transfusion Research Center, Central South University, Changsha, 410007, China

    Ning Li

Authors
  1. Sheng-lan Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xue-gong Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jie Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xing-wang Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Si-ya Pei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yi-xiang Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ning Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ze-bing Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ZBH: Conceptualization, project design, and guidance, Funding acquisition, project administration. XGF, JW, YW: writing—review & editing. SLC: Writing—original draft, data curation, formal analysis, visualization. SYP, YXZ, JC: Methodology, investigation. XWH, YH, NL: Writing—review & editing, methodology. All authors read and approved the final version of the manuscript.

Corresponding author

Correspondence to Ze-bing Huang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cai, Sl., Fan, Xg., Wu, J. et al. CB2R agonist GW405833 alleviates acute liver failure in mice via inhibiting HIF-1α-mediated reprogramming of glycometabolism and macrophage proliferation. Acta Pharmacol Sin 44, 1391–1403 (2023). https://doi.org/10.1038/s41401-022-01037-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41401-022-01037-8

Keywords

Search

Advanced search

Quick links